Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
C Citigroup	$124.76 -0.5%	$122.21	$74.30 ▼ $135.29	$212.79B	1.14	13.64 million shs	7.93 million shs
NTLA Intellia Therapeutics	$13.68 +1.8%	$13.52	$6.83 ▼ $28.25	$1.91B	1.93	5.50 million shs	4.52 million shs
NVAX Novavax	$10.32 -6.9%	$8.85	$6.13 ▼ $11.97	$1.70B	2.37	5.01 million shs	7.39 million shs
NVO Novo Nordisk A/S	$45.51 +2.2%	$40.67	$35.12 ▼ $81.44	$203.19B	0.77	20.96 million shs	14.57 million shs
SEPN Septerna	$31.05 +4.2%	$25.24	$9.11 ▼ $32.63	$1.40B	2.21	311,677 shs	219,147 shs
SNY Sanofi	$44.29 -0.3%	$45.62	$42.33 ▼ $52.68	$108.02B	0.35	3.62 million shs	2.14 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
C Citigroup	-1.17%	+0.41%	-2.96%	+7.88%	+66.15%
NTLA Intellia Therapeutics	+6.58%	+9.62%	+3.27%	-5.88%	+44.21%
NVAX Novavax	+6.02%	+19.63%	+37.51%	-0.89%	+50.27%
NVO Novo Nordisk A/S	+0.75%	-1.06%	+8.27%	+18.53%	-36.65%
SEPN Septerna	-2.81%	+6.35%	+18.73%	-1.62%	+208.70%
SNY Sanofi	+0.63%	-0.54%	-3.20%	-8.11%	-15.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
C Citigroup	$124.76 -0.5%	$122.21	$74.30 ▼ $135.29	$212.79B	1.14	13.64 million shs	7.93 million shs
NTLA Intellia Therapeutics	$13.68 +1.8%	$13.52	$6.83 ▼ $28.25	$1.91B	1.93	5.50 million shs	4.52 million shs
NVAX Novavax	$10.32 -6.9%	$8.85	$6.13 ▼ $11.97	$1.70B	2.37	5.01 million shs	7.39 million shs
NVO Novo Nordisk A/S	$45.51 +2.2%	$40.67	$35.12 ▼ $81.44	$203.19B	0.77	20.96 million shs	14.57 million shs
SEPN Septerna	$31.05 +4.2%	$25.24	$9.11 ▼ $32.63	$1.40B	2.21	311,677 shs	219,147 shs
SNY Sanofi	$44.29 -0.3%	$45.62	$42.33 ▼ $52.68	$108.02B	0.35	3.62 million shs	2.14 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
C Citigroup	-1.17%	+0.41%	-2.96%	+7.88%	+66.15%
NTLA Intellia Therapeutics	+6.58%	+9.62%	+3.27%	-5.88%	+44.21%
NVAX Novavax	+6.02%	+19.63%	+37.51%	-0.89%	+50.27%
NVO Novo Nordisk A/S	+0.75%	-1.06%	+8.27%	+18.53%	-36.65%
SEPN Septerna	-2.81%	+6.35%	+18.73%	-1.62%	+208.70%
SNY Sanofi	+0.63%	-0.54%	-3.20%	-8.11%	-15.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
C Citigroup	2.80	Moderate Buy	$137.62	10.30% Upside
NTLA Intellia Therapeutics	2.35	Hold	$20.25	48.03% Upside
NVAX Novavax	2.10	Hold	$12.13	17.49% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	44.07% Upside
SEPN Septerna	2.80	Moderate Buy	$43.13	38.89% Upside
SNY Sanofi	2.47	Hold	$51.00	15.15% Upside

Current Analyst Ratings Breakdown

Latest SEPN, C, NVAX, NVO, NTLA, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
5/13/2026	NTLA Intellia Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$13.00 ➝ $17.00
5/13/2026	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $25.00
5/13/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
5/12/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
5/12/2026	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $49.00
5/12/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$12.00
5/8/2026	C Citigroup	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$145.00
5/8/2026	C Citigroup	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$140.00 ➝ $153.00
5/7/2026	NVAX Novavax	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
5/6/2026	NVAX Novavax	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$8.00 ➝ $9.00

(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
C Citigroup	$168.30B	1.26	$11.67 per share	10.69	$113.17 per share	1.10
NTLA Intellia Therapeutics	$67.67M	28.25	N/A	N/A	$4.44 per share	3.08
NVAX Novavax	$596.34M	2.85	$3.46 per share	2.98	($0.88) per share	-11.73
NVO Novo Nordisk A/S	$46.80B	4.34	$4.83 per share	9.43	$7.12 per share	6.39
SEPN Septerna	$45.95M	30.46	N/A	N/A	$8.40 per share	3.70
SNY Sanofi	$49.35B	2.19	$7.09 per share	6.25	$35.10 per share	1.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
C Citigroup	$14.31B	$8.07	15.46	10.04	0.57	9.35%	9.19%	0.67%	7/14/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.54	N/A	N/A	N/A	-597.04%	-57.47%	-46.24%	8/6/2026 (Estimated)
NVAX Novavax	$440.30M	-$0.58	N/A	N/A	N/A	-14.73%	-14.82%	1.23%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.68	13.23	3.94	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.81	N/A	N/A	N/A	-49.88%	-12.72%	-8.87%	8/10/2026 (Estimated)
SNY Sanofi	$8.84B	$3.58	12.37	8.50	1.09	16.95%	13.39%	7.58%	7/30/2026 (Estimated)

Latest SEPN, C, NVAX, NVO, NTLA, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2026	Q1 2026	SEPN Septerna	-$0.4167	-$0.19	+$0.2267	-$0.19	$16.98 million	$26.52 million
5/11/2026	Q1 2026	NTLA Intellia Therapeutics	-$0.92	-$0.81	+$0.11	-$0.81	$13.81 million	$15.05 million
5/6/2026	Q1 2026	NVAX Novavax	-$0.25	-$0.06	+$0.19	-$0.06	$79.81 million	$118.90 million
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/14/2026	Q1 2026	C Citigroup	$2.63	$3.06	+$0.43	$3.06	$22.96 billion	$24.63 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion
3/9/2026	Q4 2025	SEPN Septerna	-$0.23	-$0.24	-$0.01	-$0.24	$20.44 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
C Citigroup	$2.40	1.92%	+2.61%	29.74%	2 Years
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
NVO Novo Nordisk A/S	$1.75	3.85%	+21.74%	41.08%	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.76	3.97%	+6.46%	49.16%	N/A

Latest SEPN, C, NVAX, NVO, NTLA, and SNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/14/2026	SNY Sanofi	annual	$2.4225	5.59%	5/4/2026	5/4/2026	6/3/2026
4/2/2026	C Citigroup	quarterly	$0.60	1.91%	5/4/2026	5/4/2026	5/22/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
C Citigroup	1.59	0.99	0.99
NTLA Intellia Therapeutics	N/A	6.10	6.10
NVAX Novavax	N/A	2.48	2.45
NVO Novo Nordisk A/S	0.59	0.79	0.56
SEPN Septerna	N/A	4.71	4.71
SNY Sanofi	0.17	1.01	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
C Citigroup	71.72%
NTLA Intellia Therapeutics	88.77%
NVAX Novavax	53.04%
NVO Novo Nordisk A/S	11.54%
SEPN Septerna	N/A
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
C Citigroup	0.11%
NTLA Intellia Therapeutics	3.10%
NVAX Novavax	1.00%
NVO Novo Nordisk A/S	0.07%
SEPN Septerna	4.30%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
C Citigroup	226,000	1.71 billion	1.70 billion	Optionable
NTLA Intellia Therapeutics	600	139.72 million	135.39 million	Optionable
NVAX Novavax	1,990	164.44 million	162.79 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
SEPN Septerna	N/A	45.08 million	43.14 million	N/A
SNY Sanofi	74,846	2.44 billion	2.41 billion	Optionable

SEPN, C, NVAX, NVO, NTLA, and SNY Headlines

Recent News About These Companies

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28 at 1:00 AM | globenewswire.com

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

May 22, 2026 | zacks.com

sanofi - SNY

May 21, 2026 | foxbusiness.com

Sanofi (NASDAQ:SNY) Given Consensus Recommendation of "Hold" by Brokerages

May 20, 2026 | americanbankingnews.com

Sanofi: Information concerning the total number of voting rights and shares - April 2026

May 19, 2026 | globenewswire.com

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

May 19, 2026 | zacks.com

Sanofi says rare lung disease drug outperforms standard care in trial

May 18, 2026 | reuters.com

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

May 18, 2026 | globenewswire.com

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

May 13, 2026 | fool.com

Erste Group Bank Decreases Earnings Estimates for Sanofi

May 11, 2026 | marketbeat.com

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

May 8, 2026 | zacks.com

Truist Financial Corp Sells 37,780 Shares of Sanofi $SNY

May 7, 2026 | marketbeat.com

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

May 6, 2026 | reuters.com

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

May 6, 2026 | prnewswire.com

Sanofi $SNY Shares Sold by UBS Group AG

May 6, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Sets New 1-Year Low - Should You Sell?

May 5, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Shares Gap Down Following Analyst Downgrade

May 4, 2026 | marketbeat.com

M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY

May 3, 2026 | marketbeat.com

Morgan Stanley Downgrades Sanofi (NASDAQ:SNY) to Equal Weight

May 1, 2026 | marketbeat.com

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

April 29, 2026 | globenewswire.com

Sanofi (NASDAQ:SNY) Upgraded at Argus

April 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SEPN, C, NVAX, NVO, NTLA, and SNY Company Descriptions

Citigroup NYSE:C

$124.76 -0.63 (-0.50%)

Closing price 03:59 PM Eastern

Extended Trading

$124.75 -0.01 (-0.01%)

As of 05:41 PM Eastern

Citigroup Inc., a diversified financial service holding company, provides various financial product and services to consumers, corporations, governments, and institutions worldwide. It operates through five segments: Services, Markets, Banking, U.S. Personal Banking, and Wealth. The Services segment includes Treasury and Trade Solutions, which provides cash management, trade, and working capital solutions to multinational corporations, financial institutions, and public sector organizations; and Securities Services, such as cross-border support for clients, local market expertise, post-trade technologies, data solutions, and various securities services solutions. The Markets segment offers sales and trading services for equities, foreign exchange, rates, spread products, and commodities to corporate, institutional, and public sector clients; and market-making services, including asset classes, risk management solutions, financing, prime brokerage, research, securities clearing, and settlement. The banking segment includes investment banking; advisory services related to mergers and acquisitions, divestitures, restructurings, and corporate defense activities; and corporate lending, which includes corporate and commercial banking. The U.S. Personal Banking segment provides co-branded cards and retail banking services. The Wealth segment provides financial services to high-net-worth clients through banking, lending, mortgages, investment, custody, and trust product offerings; and to professional industries, including law firms, consulting groups, accounting, and asset management. The company was founded in 1812 and is headquartered in New York, New York.

Intellia Therapeutics NASDAQ:NTLA

$13.68 +0.24 (+1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$13.72 +0.04 (+0.26%)

As of 05:39 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$10.32 -0.77 (-6.94%)

Closing price 04:00 PM Eastern

Extended Trading

$10.32 +0.00 (+0.05%)

As of 05:41 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novo Nordisk A/S NYSE:NVO

$45.51 +0.96 (+2.15%)

Closing price 03:59 PM Eastern

Extended Trading

$45.56 +0.06 (+0.12%)

As of 05:41 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Septerna NASDAQ:SEPN

$31.05 +1.26 (+4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$31.17 +0.12 (+0.38%)

As of 04:26 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Sanofi NASDAQ:SNY

$44.29 -0.14 (-0.32%)

Closing price 04:00 PM Eastern

Extended Trading

$44.29 0.00 (0.00%)

As of 05:08 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEPN, C, NVAX, NVO, NTLA, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEPN, C, NVAX, NVO, NTLA, and SNY Earnings

Compare Dividends

Latest SEPN, C, NVAX, NVO, NTLA, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEPN, C, NVAX, NVO, NTLA, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SEPN, C, NVAX, NVO, NTLA, and SNY Company Descriptions

Citigroup NYSE:C

Intellia Therapeutics NASDAQ:NTLA

Novavax NASDAQ:NVAX

Novo Nordisk A/S NYSE:NVO

Septerna NASDAQ:SEPN

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools